Cargando…

Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease—A Comparative Clinical Study

(1) Background: Hyperphosphatemia is correlated with an increased rate of mortality and morbidity due to cardiovascular diseases in chronic kidney disease (CKD) patients. It can be improved by restricting dietary intake of phosphate and oral phosphate binders, such as lanthanum carbonate and sevelam...

Descripción completa

Detalles Bibliográficos
Autores principales: Nain, Parminder, Nayak, Narendra, Maj, Mary C., Singh, Rohit Kumar, Kaur, Jaspreet, Jeong, Yujin, Maity, Sabyasachi, Nath, Reetuparna, Hilgers, Robert H., Nauhria, Shreya, Nauhria, Samal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960578/
https://www.ncbi.nlm.nih.gov/pubmed/36827665
http://dx.doi.org/10.3390/pharmacy11010027
_version_ 1784895546481180672
author Nain, Parminder
Nayak, Narendra
Maj, Mary C.
Singh, Rohit Kumar
Kaur, Jaspreet
Jeong, Yujin
Maity, Sabyasachi
Nath, Reetuparna
Hilgers, Robert H.
Nauhria, Shreya
Nauhria, Samal
author_facet Nain, Parminder
Nayak, Narendra
Maj, Mary C.
Singh, Rohit Kumar
Kaur, Jaspreet
Jeong, Yujin
Maity, Sabyasachi
Nath, Reetuparna
Hilgers, Robert H.
Nauhria, Shreya
Nauhria, Samal
author_sort Nain, Parminder
collection PubMed
description (1) Background: Hyperphosphatemia is correlated with an increased rate of mortality and morbidity due to cardiovascular diseases in chronic kidney disease (CKD) patients. It can be improved by restricting dietary intake of phosphate and oral phosphate binders, such as lanthanum carbonate and sevelamer carbonate. (2) Objective: To evaluate the clinical efficacy of sevelamer carbonate in comparison to lanthanum carbonate as phosphate binders for the treatment of hyperphosphatemia in CKD patients. (3) Methods: A randomized control comparative clinical study was conducted for one year on 150 CKD patients associated with hyperphosphatemia, divided into two groups, i.e., Group 1 (n = 75) treated with sevelamer carbonate 800 mg thrice daily and Group 2 (n = 75) treated with lanthanum carbonate 500 mg thrice daily. The patients were assessed at the time of enrollment in the study, after three months and after six months from baseline for different parameters, i.e., complete blood count, liver function tests, renal function tests, electrolytes, and serum phosphate level. (4) Results: 150 CKD patients aged 51–60 participated in the study. The mean age of patients was 54 ± 4.6 years, and males (55.71%) were more common than females (44.29%). Hypertension was the common comorbidity in both groups with chronic kidney disease. After six months of treatment, the mean serum phosphate level was significantly decreased from 8.31 ± 0.09 mg/dL to 5.11 ± 0.18 (38%) in Group 1 and from 8.79 ± 0.28 mg/dl to 4.02 ± 0.12 (54%; p < 0.05) in Group 2, respectively. In both groups, no significant difference was found in other parameters such as parathyroid hormone, calcium, uric acid, LFT, RFT, CBC, etc. (5) Conclusion: Lanthanum carbonate is more efficacious in lowering serum phosphate concentrations and effectively managing hyperphosphatemia as compared to sevelamer carbonate.
format Online
Article
Text
id pubmed-9960578
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99605782023-02-26 Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease—A Comparative Clinical Study Nain, Parminder Nayak, Narendra Maj, Mary C. Singh, Rohit Kumar Kaur, Jaspreet Jeong, Yujin Maity, Sabyasachi Nath, Reetuparna Hilgers, Robert H. Nauhria, Shreya Nauhria, Samal Pharmacy (Basel) Article (1) Background: Hyperphosphatemia is correlated with an increased rate of mortality and morbidity due to cardiovascular diseases in chronic kidney disease (CKD) patients. It can be improved by restricting dietary intake of phosphate and oral phosphate binders, such as lanthanum carbonate and sevelamer carbonate. (2) Objective: To evaluate the clinical efficacy of sevelamer carbonate in comparison to lanthanum carbonate as phosphate binders for the treatment of hyperphosphatemia in CKD patients. (3) Methods: A randomized control comparative clinical study was conducted for one year on 150 CKD patients associated with hyperphosphatemia, divided into two groups, i.e., Group 1 (n = 75) treated with sevelamer carbonate 800 mg thrice daily and Group 2 (n = 75) treated with lanthanum carbonate 500 mg thrice daily. The patients were assessed at the time of enrollment in the study, after three months and after six months from baseline for different parameters, i.e., complete blood count, liver function tests, renal function tests, electrolytes, and serum phosphate level. (4) Results: 150 CKD patients aged 51–60 participated in the study. The mean age of patients was 54 ± 4.6 years, and males (55.71%) were more common than females (44.29%). Hypertension was the common comorbidity in both groups with chronic kidney disease. After six months of treatment, the mean serum phosphate level was significantly decreased from 8.31 ± 0.09 mg/dL to 5.11 ± 0.18 (38%) in Group 1 and from 8.79 ± 0.28 mg/dl to 4.02 ± 0.12 (54%; p < 0.05) in Group 2, respectively. In both groups, no significant difference was found in other parameters such as parathyroid hormone, calcium, uric acid, LFT, RFT, CBC, etc. (5) Conclusion: Lanthanum carbonate is more efficacious in lowering serum phosphate concentrations and effectively managing hyperphosphatemia as compared to sevelamer carbonate. MDPI 2023-02-02 /pmc/articles/PMC9960578/ /pubmed/36827665 http://dx.doi.org/10.3390/pharmacy11010027 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nain, Parminder
Nayak, Narendra
Maj, Mary C.
Singh, Rohit Kumar
Kaur, Jaspreet
Jeong, Yujin
Maity, Sabyasachi
Nath, Reetuparna
Hilgers, Robert H.
Nauhria, Shreya
Nauhria, Samal
Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease—A Comparative Clinical Study
title Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease—A Comparative Clinical Study
title_full Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease—A Comparative Clinical Study
title_fullStr Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease—A Comparative Clinical Study
title_full_unstemmed Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease—A Comparative Clinical Study
title_short Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease—A Comparative Clinical Study
title_sort efficacy of lanthanum carbonate and sevelamer carbonate as phosphate binders in chronic kidney disease—a comparative clinical study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960578/
https://www.ncbi.nlm.nih.gov/pubmed/36827665
http://dx.doi.org/10.3390/pharmacy11010027
work_keys_str_mv AT nainparminder efficacyoflanthanumcarbonateandsevelamercarbonateasphosphatebindersinchronickidneydiseaseacomparativeclinicalstudy
AT nayaknarendra efficacyoflanthanumcarbonateandsevelamercarbonateasphosphatebindersinchronickidneydiseaseacomparativeclinicalstudy
AT majmaryc efficacyoflanthanumcarbonateandsevelamercarbonateasphosphatebindersinchronickidneydiseaseacomparativeclinicalstudy
AT singhrohitkumar efficacyoflanthanumcarbonateandsevelamercarbonateasphosphatebindersinchronickidneydiseaseacomparativeclinicalstudy
AT kaurjaspreet efficacyoflanthanumcarbonateandsevelamercarbonateasphosphatebindersinchronickidneydiseaseacomparativeclinicalstudy
AT jeongyujin efficacyoflanthanumcarbonateandsevelamercarbonateasphosphatebindersinchronickidneydiseaseacomparativeclinicalstudy
AT maitysabyasachi efficacyoflanthanumcarbonateandsevelamercarbonateasphosphatebindersinchronickidneydiseaseacomparativeclinicalstudy
AT nathreetuparna efficacyoflanthanumcarbonateandsevelamercarbonateasphosphatebindersinchronickidneydiseaseacomparativeclinicalstudy
AT hilgersroberth efficacyoflanthanumcarbonateandsevelamercarbonateasphosphatebindersinchronickidneydiseaseacomparativeclinicalstudy
AT nauhriashreya efficacyoflanthanumcarbonateandsevelamercarbonateasphosphatebindersinchronickidneydiseaseacomparativeclinicalstudy
AT nauhriasamal efficacyoflanthanumcarbonateandsevelamercarbonateasphosphatebindersinchronickidneydiseaseacomparativeclinicalstudy